Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Has Consensus Target Price of $8.20

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned an average rating of “Reduce” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $8.20.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Friday, July 17th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Fulcrum Therapeutics in the second quarter worth approximately $32,297,000. Nantahala Capital Management LLC bought a new position in shares of Fulcrum Therapeutics during the 2nd quarter valued at $20,038,646. Siren L.L.C. lifted its stake in shares of Fulcrum Therapeutics by 20.5% in the 1st quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 400,000 shares during the last quarter. First Turn Management LLC acquired a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at $21,406,000. Finally, ADAR1 Capital Management LLC bought a new stake in Fulcrum Therapeutics in the second quarter worth $5,728,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Stock Performance

FULC opened at $3.69 on Friday. Fulcrum Therapeutics has a one year low of $2.83 and a one year high of $15.74. The company has a market capitalization of $281.54 million, a PE ratio of -3.05 and a beta of 2.63. The stock’s fifty day moving average is $3.79 and its 200-day moving average is $5.04.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, equities research analysts forecast that Fulcrum Therapeutics will post -0.6 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases that affect skeletal muscle and other tissues. The company uses its FulcrumSeek drug-discovery platform to identify molecular targets and potential therapies for conditions in which the underlying biology is well characterized but treatment options remain limited.

Fulcrum’s lead product candidate is losmapimod, an investigational oral therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare inherited muscle-wasting disorder.